SCHEMBL29682103

SCHEMBL29682103

Brc1cnc2c(c1)CN=N2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.34
KMT2A Q03164 1/20 0.34
DYRK1A Q13627 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
JAK2 O60674 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
IGF1R P08069 1/20 0.32
FGFR1 P11362 1/20 0.32
PDGFRA P16234 1/20 0.32
PRKACA P17612 1/20 0.32
FLT1 P17948 1/20 0.32
LTK P29376 1/20 0.32
GRK5 P34947 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25699756 0.67 HTT (0.34) HTTKMT2ADYRK1A
SCHEMBL20099798 0.67 HTT (0.34) HTTKMT2ADYRK1ASMN1; SMN2CHEK1
SCHEMBL29694373 0.65 GSK3A (0.37) KDR
SCHEMBL29809560 0.64 HTT (0.32) HTTKMT2A
SCHEMBL15290415 0.64 HTT (0.39) HTTKMT2ADYRK1ASMN1; SMN2CHEK1
SCHEMBL4201272 0.60 ABHD6 (0.35) HTTKMT2AABHD6
SCHEMBL30471092 0.60 ABHD6 (0.35) HTTKMT2AABHD6
SCHEMBL5120809 0.60 ADRA2A (0.47) HTTKMT2ADYRK1ASMN1; SMN2CDK5
SCHEMBL9403398 0.60 PRNP (0.46) HTTKMT2ADYRK1ASMN1; SMN2MAPT
SCHEMBL1500697 0.59 SMN1; SMN2 (0.48) HTTKMT2ADYRK1ASMN1; SMN2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486264-B2 Bicyclic HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-02 US disclosed
EP-3947373-B1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-14 EP disclosed
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486264-B2 Bicyclic HPK1 inhibitors PCK1, PGK1, PDXK HTT 1731/4885KMT2A 2847/4885DYRK1A 2022/4885
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS PCK1, PGK1, PDXK HTT 1731/4885KMT2A 2847/4885DYRK1A 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.